All posts by imreal

the Social Vulnerability Metric (SVM)


News Image

“The breakthrough developments of the CAT-SDoH and SVM open the door to a new approach to the measurement of SDoH,” said Robert Gibbons, Ph.D., Blum-Riese Professor, University of Chicago. “If we know a person’s zip code, the SVM items for that person’s environment can be immediately determined.”

A new research study published in Health Services Research presents the development and validation of a new metric for social vulnerability. The breakthrough development of the social vulnerability metric (SVM) opens the door to a new approach to the estimation of social vulnerability from the ecological perspective. The SVM can serve as a tool for public health policy and practice, significantly impacting the understanding of an individual’s risk based solely on their zip code.

According to the US Department of Health and Human Services, social vulnerability refers to the potential negative effects on communities caused by external stresses on human health1. Social Determinants of Health (SDoH) are environmental conditions such as economic stability, access to healthcare, or place of residence, that impact an individual’s health and well-being, often contributing to health disparities and inequities.2,3 When SDoH is accurately measured, it can help public health departments and policymakers appropriately target interventions for communities with the greatest needs.

The SVM was developed using 2018 data obtained from the Federal and publicly available Agency for Healthcare Research and Quality (AHRQ) Social Determinants of Health (SDoH) Database, a dataset of SDoH variables from data sources spanning 2009 to 2018, measured at the Zip Code Tabulation Area (ZCTA).4 ZCTAs differ from zip codes because they only include populated areas; for example zip codes that only include PO boxes are not included in ZCTAs. From these data, researchers fit a bifactor MIRT model to the reviewed set of 94 different SDoH variables to provide a single-value SVM score.5 The bifactor model was applied to data representative of 33,120 zip codes without missing data, which includes 99% of all U.S. zip codes.

The SVM was validated against several health indicators at the national, state and city level. First, the SVM was validated against nationwide age-adjusted all-cause mortality rates provided by the CDC at the county level. The SVM accounted for 46% of the nationwide variability in mortality rates (r=0.68), whereas CDC’s measure, the Social Vulnerability Index (SVI) only accounted for 12% of the variability in mortality rates (r=0.34). Second, it was validated against State of California zip-code level COVID-19 vaccination rates (r=-0.68) and emergency department visits for asthma (r=0.62 for youth and r=0.60 for adults). The negative correlations with COVID-19 vaccination rates indicate that more socially vulnerable populations had less access to COVID-19 vaccines early in the pandemic. Third, it was validated using the Chicago Department of Public Health COVID-19 mortality and vaccination rates. The associations between the SVM scores and COVID mortality and vaccination rates. The correlations across the 58 zip codes were r=0.71 for COVID mortality and r=-0.85 for first vaccination rates. Socially vulnerable communities experienced six times the rate of COVID-19 mortality compared to less socially vulnerable communities (300/100,000 versus 50/100,000 respectively) and a much lower first vaccination rate (32% versus 79% respectively).

Lead author of the study, Lauren Saulsberry, PhD, Department of Public Health Sciences, The University of Chicago along with colleagues Robert Gibbons, Ph.D., Blum-Riese Professor at the University of Chicago; Ankur Bhargava, MD, MPH, Department of Pediatrics, The University of Chicago; Sharon Zeng, BA, Pritzker School of Medicine, University of Chicago; Jason B. Gibbons, PhD, Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health; Cody Brannan, MS, University of Chicago; and Diane S. Lauderdale, PhD, University of Chicago, also developed an interactive web application.

Visitors to the SVM web application can:


  • View interactive national county and zip-code level heat maps that visualize SVM percentiles
  • View the relationship between county and zip-code SVM scores and 24 health indicators (such as asthma, diabetes, and stroke) nationally or by state
  • View or download the county or zip-code level SVM data

“Social determinants of health not only impact people’s health and wellbeing, but it can also contribute to health disparities and inequities,” said Lauren Saulsberry, PhD. “With this study, the SVM was derived from various SDoH variables from multiple nationally representative public databases using multidimensional item response theory (MIRT), ultimately providing a higher level of precision than any existing SDoH metric. The SVM offers a measurement tool improving upon the performance of existing SDoH composite measures and has broad applicability to public health that may help in directing future policies and interventions.”

Researchers also have an exciting addition to this already forward-thinking work. Adaptive Testing Technologies, developer of the CAT-MH® assessment tools, has been collecting data using the CAT-SDoH, a measure of an individual’s personal perspective of their life satisfaction. Together with the SVM, the ability to measure SDoH accurately and precisely in a population has never been greater. When combined, the SVM and CAT-SDoH further improves the adaptive assessment of an individual’s true social vulnerability, reflected as a synthesis of both their ecological and personal perspective.

“The breakthrough developments of the CAT-SDoH and SVM open the door to a new approach to the measurement of SDoH,” said Robert Gibbons, Ph.D., Blum-Riese Professor at the University of Chicago.” “The SVM provides a single measure of SDoH that better quantifies associations with health outcomes.

We now have the technology to adaptively measure SDoH from both ecological and personal perspectives. If we know a person’s zip code, the SVM items for that person’s environment can be immediately determined.”

About the Study

The objective of this study was to derive and validate a new ecological measure of the social determinants of health (SDoH), calculable at the zip code or county level. The SVM was constructed from U.S. zip-code tabulation area level measures from survey data using multidimensional Item Response Theory and validated using outcomes including all-cause mortality, COVID-19 vaccination and mortality rates, and emergency department visits for asthma. The SVM was also compared with the CDC/ATSDR Social Vulnerability Index (SVI) to determine convergent validity and differential predictive accuracy.

About Adaptive Testing Technologies

Adaptive Testing Technologies (ATT) is the leader in the design, testing, and implementation of large-scale, cloud-based mental health assessment tools based on Computerized Adaptive Testing (CAT) and Computerized Adaptive Diagnostic (CAD) technologies. These tools are utilized by health professionals to assess a variety of mental health conditions – including depression, anxiety, mania, psychosis, PTSD, substance use disorder, suicide risk, ADHD, and assess Social Determinants of Health. The CAT-MH® and K-CAT® represent the first and only validated, comprehensive, multidimensional item-response-theory-based adaptive screening and measurement systems in the world. They provide levels of precision and accuracy that is far beyond what can be achieved using traditional fixed-length mental health assessment scales and can be administered anywhere at any

frequency, in or out of the clinic, to any sized population. ATT’s tools are currently being utilized in emergency departments, psychiatric and primary care clinics, telemedicine, student health clinics, perinatal medicine clinics, child welfare settings, substance use disorder programs, federal and state mental health programs, employee assistance programs, and the judicial system. The tools are available and are currently being used worldwide.

###

1. https://health.gov/healthypeople/priority-areas/social-determinants-health

2. World Health Organization. Social determinants of health. 2022. Accessed April 21, 2022.

3. US Department of Health and Human Services, Healthy People 2030. Social Determinants of Health. Accessed April 21, 2022.

4.Agency for Healthcare Research and Quality (AHRQ), Rockville, MD. Social Determinants Content last reviewed June 2021. Accessed April 21, 2022.

5. Gibbons RD, Bock RD, Hedeker D, et al. Full-Information Item Bifactor Analysis of Graded Response Data. Applied Psychological Measurement. 2007;31(1):4-19.

6. United States Postal Service (USPS). Postal Facts. Available at: https://facts.usps.com/42000-zip-codes/ Accessed April 21, 2022

MEDIA CONTACT:

Hannah Wulczyn, MPA

Adaptive Testing Technologies

media@adaptivetestingtechnologies.com

312.878.6490, Ext. 505

MDsave Partners with ViewFi Health to Launch Industry Leading Orthopedic & Musculoskeletal Solution


MDsave, the nation’s leading online healthcare services platform connecting providers, employers, and patients to transparent, transactable, and quality healthcare, announced today a new exclusive partnership with ViewFi Health.

ViewFi Health is the world’s first virtual orthopedic practice. ViewFi Health offers personalized and hyper-accurate orthopedic and musculoskeletal (MSK) care while reducing costs, streamlining the path to recovery, and prioritizing improved patient outcomes – all virtually. ViewFi Health acts as the front door to orthopedic and MSK care, offering a convenient and easy way for patients to receive the same level of high-quality care as an in-person visit with an orthopedic surgeon, but from the comfort of their home. ViewFi streamlines the care experience and helps patients receive the correct diagnosis and plan of care faster than ever before so they can return to a pain-free life as fast as possible.

MDsave’s network and proprietary technology complement ViewFi Health’s current service offerings, providing a comprehensive solution to their customers from consultation and diagnosis to treatment and post-acute care. ViewFi Health’s excellence in virtual diagnostics and virtual physical therapy (PT) for MSK conditions is now strengthened by MDsave’s national imaging, in-person PT, and surgical networks.

“We are looking forward to our partnership with MDsave knowing we will see positive outcomes for both companies as well as the patients we serve,” says Michael Williamson, CoFounder & CEO, ViewFi Health. “We are focused together on providing the very best patient experience starting with a diagnosis and definitive plan of care as the first and most important step of pain recovery.”

MDsave works directly with a nationwide network of health systems, imaging centers, surgery centers, and providers to create shoppable, fully-bundled medical procedures that patients and employers can purchase online through MDsave’s patented technology at transparent, upfront prices with no surprise bills. The MDsave platform also connects self-funded employers directly to local hospitals and health systems, building volume and loyalty in the local community through innovative and patented digital workflows.

“We are excited for the opportunities arising out of our new partnership with ViewFi Health,” says Charlie Byrge, chief operating officer at MDsave. “ViewFi Health allows us to help even more patients by bringing MDsave into the virtual healthcare space, and further ViewFi Health’s mission of improving access to world-class diagnostic care.”

About MDsave

Headquartered in Nashville, TN, MDsave is the nation’s leading online medical service marketplace connecting providers, employers, and consumers to affordable, reliable, high-quality healthcare at fair, transparent prices. Through innovative technology, MDsave simplifies the healthcare billing process for patients and providers through bundled pricing and upfront payment. MDsave’s patented technology also supports employers and payers to deliver more value to employees and policyholders, minimizing out-of-pocket deductible costs. For more information, visit http://www.mdsave.com/.

About ViewFi Health

ViewFi Health was founded with a mission to innovate and improve the way patients access and receive world-class orthopedic and MSK care. ViewFi Health is the world’s first virtual orthopedic practice offering personalized and hyper-accurate orthopedic and musculoskeletal care while reducing costs, streamlining the path to recovery, and prioritizing improved patient outcomes. ViewFi Health brings top orthopedic/MSK providers and surgeons directly to patients, virtually, while supporting the patient’s entire journey, from intake and diagnosis to treatment and recovery. ViewFi Health offers it all in one place. For more information visit us at: https://viewfi.com.

Share article on social media or email:

Catalent and Ethicann Sign Development and License Agreement for New Fast-Dissolve Cannabinoid-Based Treatments


Zydis can be used to rapidly administer therapeutic doses of active drug, and we look forward to continuing the relationship and applying all our expertise in developing, launching and supplying new differentiated therapies with the potential to improve patient care across a range of indications.

Catalent, the global leader in enabling the development and supply of better treatments across multiple modalities, and Ethicann Pharmaceuticals Inc., a Canadian/U.S. specialty pharmaceutical company focused on the development of high-value cannabinoid drug therapies, today announced that the companies had executed a development and license agreement to develop Ethicann’s clinical drug pipeline using Catalent’s proprietary Zydis® orally disintegrating tablet (ODT) technology.

Under the terms of the license, financial details of which have not been disclosed, Catalent will look to develop Ethicann’s cannabidiol (CBD) and tetrahydrocannabinol (THC) pharmaceutical products using its Zydis technology in clinical trials across a range of indications including multiple sclerosis (MS) spasticity, chemotherapy-induced nausea and vomiting, chronic pain for cancer, and epilepsy. This agreement follows a feasibility study that showed the Ethicann EPI-002 candidate to treat MS spasticity formulated with Zydis ODT dissolves in approximately three seconds without the need for water and is rapidly absorbed through the lingual and sublingual mucosa into the blood, providing therapeutic advantage by bypassing the liver, which typically removes 30-45% of cannabinoids absorbed through the stomach. Ethicann anticipates performing a human bioequivalence study of EPI-002 in late 2023-early 2024, which is required for new drug approvals in Canada.

Zydis is a unique, freeze-dried, oral solid dosage form that disperses almost instantly in the mouth, without the need for water and has a dispersion speed of as little as three seconds. Zydis is the world’s fastest and best-in-class orally disintegrating tablet and is used in over 35 drugs approved in 60 countries.

“Ethicann believes that Zydis ODT delivery technology, when incorporated into its cannabinoid drugs, has the potential to provide competitive advantages in the marketplace, as well as enhanced safety profiles,” commented Robert Auritt, President/Chief Executive Officer, Ethicann Pharmaceuticals Inc.

“We have been working with Ethicann for several years, and the Zydis technology has shown to be a superior delivery technology for its pipeline candidates, offering the advantages of improved patient acceptance, adherence, and convenience,” said Tom Hawkeswood, President, Division Head of Pharma Product Delivery, Catalent. “Zydis ODT can be used to rapidly administer therapeutic doses of active drug, and we look forward to continuing the relationship and applying all our expertise in developing, launching and supplying new differentiated therapies with the potential to improve patient care across a range of CNS indications.”

Catalent’s 250,000-square-foot site in Swindon, U.K., houses the company’s Zydis development and manufacturing operation, which produces over one billion tablets annually and employs more than 600 people.

About Ethicann Pharmaceuticals

Ethicann (Canada/US) has positioned itself as a cost-efficient pharmaceutical development company, using established multinational partners to source ultra-purified APIs and the proprietary sublingual Zydis orally disintegrating tablet (ODT) technology. Ethicann is leveraging these partnerships to formulate and further develop cannabinoid-based pharmaceutical drug products and avoid deploying capital in building and fully staffing its own facilities. This pharma business reformulation strategy coupled with the use of abbreviated regulatory approval pathways in various countries will also be used for rapid development of its Zydis-based pipeline drugs to treat other clinical indications. Ethicann has had successful FDA and Health Canada interactions, which have focused its regulatory developmental and clinical activities. For more information see: http://www.ethicann-pharma.com

About Catalent

Catalent is the global leader in enabling pharma, biotech, and consumer health partners to optimize product development, launch, and full life-cycle supply for patients around the world. With broad and deep scale and expertise in development sciences, delivery technologies, and multi-modality manufacturing, Catalent is a preferred industry partner for personalized medicines, consumer health brand extensions, and blockbuster drugs.

Catalent helps accelerate over 1,000 partner programs and launch over 150 new products every year. Its flexible manufacturing platforms at over 50 global sites supply around 80 billion doses of nearly 8,000 products annually. Catalent’s expert workforce of approximately 18,000 includes more than 3,000 scientists and technicians.

Headquartered in Somerset, New Jersey, the company generated nearly $5 billion in revenue in its 2022 fiscal year. For more information, visit http://www.catalent.com.

More products. Better treatments. Reliably supplied.™

Share article on social media or email:

Baltimore-based Techstars Equitech Accelerator Names Startups in New Cohort


The future belongs to creative builders and smart risk-takers

Techstars Equitech Accelerator announces ten early-stage companies selected to participate in a three-month immersive accelerator program. The new cohort marks the second startup class spanning verticals and industries with emerging tech solutions. Hailing from Baltimore and cities across the nation, each founder will benefit from access to capital, business development and high-tier mentorship.

Parallel with Techstars’ global ethos, the accelerator will foster high-growth startups that are grounded in the values of diversity, led by founders from underestimated communities, or developing technologies that increase access and equity. The program boasts a wealth of global success from startups who have experienced the definitive model that redefines equity, access, and belonging across tech startups and non-tech scaleups.

Led by Managing Director, Adam Phillips, who brings legal, business and deep-knowledge investment experience; the accelerator is a collaboration between Techstars, the worldwide network that helps entrepreneurs succeed, and UpSurge Baltimore, an organization that envisions building the country’s first Equitech city while cultivating a tech-for-all ecosystem in Baltimore. Harnessing the creative ingenuity of Baltimoreans and beyond, leaders throughout the City of Baltimore are aligning to build an inclusive innovation economy led by this alliance.

“The future belongs to creative builders and smart risk-takers so we’re excited to announce the Techstars Equitech Accelerator’s second class of ten early-stage companies,” Phillip states. “This was an extremely competitive application process that has produced an impressive group of high-growth, tech and tech-enabled companies that we have the privilege of working with for the next thirteen weeks.”

Mentorship is a distinguishing value of the program. Individuals with deep, industry investment or entrepreneurship experience such as Delali Dzirasa, Founder/CEO of Fearless and Christy Wyskiel, Executive Director of Johns Hopkins Technology Ventures are among the expanding Baltimore network that will serve this year’s cohort.

Throughout the thirteen-week program, Techstars Equitech Accelerator will be focused on the needs of a diverse company portfolio and the significant mentors who will help accelerate each founder’s business success. The program will culminate on April 6, 2023 with “Demo Day”, a public showcase attended by potential investors, stakeholders and community members.

TECHSTARS EQUITECH CLASS OF 2023: 


  • BlackHedge (Jacksonville, FL) – a mobile investing app that enhances the trading experience for end users with artificial intelligence and data analytics. blackhedge.io
  • CyDeploy Inc. (Baltimore, MD) – an automated testing system that enables security and functional testing and changes without disrupting operations. cydeploy.com 
  • TechRow (New York, NY) – an immersive media network that is reimagining education by making augmented and virtual reality learning experiences accessible to all students. techrow.org 
  • THE MOST Inc. (Washington, DC) – a marketplace and hub for natural hair enthusiasts that provides tech-forward, all-in-one styling solutions for the textured hair care market. themostcurls.co 
  • Vectech Inc. (Baltimore, MD) – an AI diagnostic entomology system to identify damaging insects that spread disease and cause agricultural or economic loss. vectech.io 
  • ReBokeh Vision Technologies (Baltimore, MD) – an app-based assistive technology system for people with moderate vision impairments that allows them to personalize how they see the world. rebokeh.com 
  • Frontline Gig (Norfolk, VA) – an on-demand, gig staffing platform that helps cities to respond to clean-ups and green jobs faster using AI and hourly workers. frontlinegig.com 
  • Sanitas Health, Inc (Los Angeles, CA) – a behavioral health platform designed to make mental health services radically accessible and inclusive for BIPOC and low-income populations. gotosanitas.com 
  • Divaneering Lab Inc. (Baltimore, MD) – a beauty-tech hair drying device that provides an efficient method to drying detached hairpieces without damaging heat. meetspundle.com   
  • Pickups Technologies Inc. (Brooklyn, NY) – a hyperlocal supply chain partner for retailers and shipping carriers that enables them to sustainably optimize their fulfillment and delivery capabilities. usepickups.com 

ABOUT TECHSTARS

The Techstars worldwide network helps entrepreneurs succeed. Founded in 2006, Techstars began with three simple ideas—entrepreneurs create a better future for everyone, collaboration drives innovation, and great ideas can come from anywhere. Now Techstars is on a mission to enable every person on the planet to contribute to, and benefit from, the success of entrepreneurs. In addition to operating accelerator programs and venture capital funds, Techstars does this by connecting startups, investors, corporations, and cities to help build thriving startup communities. Techstars has invested in more than 3,100 companies with a combined market cap of approximately $156 billion. techstars.com

ABOUT UPSURGE

UpSurge Baltimore is mobilizing Baltimore’s unparalleled entrepreneurial assets into a leading US innovation city, and the country’s first Equitech city. a top-tier tech city where diverse entrepreneurs found transformative companies; where the tech workforce of the future is growing up in our neighborhoods; where prosperity is shared across every Zip code; where the technologies reshaping society are born. UpSurge helps to launch, support, grow and celebrate high-impact startups. UpSurge is also developing strategies to attract new companies, talent and capital to Baltimore. upsurgebaltimore.com

Share article on social media or email:

Hospital M&A Activity Slowed in Q4:2022, According to Acquisition Data from LevinPro HC


News Image

“The industry faces major headwinds, such as rising labor and operation costs, staffing issues, and increased pressure from companies like CVS and Walgreens moving into outpatient care. Health system mergers highlight that scale and market penetration is the best way to compete in a tough market.”

Headwinds and market challenges took a toll on Hospital M&A activity in the fourth quarter of 2022. According to new acquisition data captured in the LevinPro HC platform, there were 19 transactions announced in the Hospital sector in Q4:22, a 10% decline from activity in Q3:22 when 21 deals were announced. Fourth quarter activity was virtually level with Q4:21 transaction volume when 18 deals were announced.

Announced spending reached $821 million in Q4:22, a decline of 89% compared with the third quarter of 2022. In Q3, Mediclinic International Ltd., a diversified international private healthcare services group founded in South Africa, was purchased for $7.42 billion by Remgro Limited and MSC Mediterranean Shipping Company, one of the largest hospital deals on record.

Although deal volume was slow, there were still several notable deal announcements, especially from large health systems. In the fourth quarter, Yale New Haven Health System, the most extensive healthcare system in Connecticut, purchased the operations and outpatient clinic services of three hospitals from Prospect Medical Holdings to expand its network in the state. In a separate deal, Prospect Medical Holdings purchased the real estate of the three hospitals from Medical Properties Trust, Inc. for $457 million, the largest deal of the fourth quarter based on disclosed price.

In December, OhioHealth closed negotiations with both Guernsey Health Systems and Van Wert Health, adding two hospitals, more than 100 beds and a collection of physician groups, outpatient clinics and home health operations to its network.

Two major health systems in Michigan, University of Michigan Health System and Sparrow Health System, merged in early December, creating a $7 billion organization and one of the largest healthcare providers in the state.

Most fourth-quarter transactions targeted systems and organizations with more than 100 beds and several facilities. Very few deals focused on critical access hospitals or community hospitals. In the 19 deals announced in Q4:22, more than 5,000 beds and 45 hospitals were acquired or involved in a merger.

“Transaction volume may have slowed, but mergers between large health systems revealed an active market nonetheless,” said Dylan Sammut, Editor of Health Care at Irving Levin Associates, which publishes the data on its LevinPro HC platform. “The industry faces major headwinds, such as rising labor and operation costs, staffing issues, and increased pressure from companies like CVS and Walgreens moving into outpatient care. Health system mergers highlight that scale and market penetration is the best way to compete in a tough market.”

All quarterly results are published in The Health Care M&A Report, which is part of the Irving Levin Associates and LevinPro investment research source. For information, or to order the reports, call 800-248-1668. Irving Levin Associates is celebrating more than 70 years of delivering exclusive M&A intelligence to its sophisticated audience of seniors housing and healthcare investors. The company was established in 1948 and has offices in New Canaan, Connecticut, and North Bethesda, Maryland. The company publishes research reports and newsletters and maintains healthcare and senior housing M&A markets databases.

Share article on social media or email:

Innophos Highlights New Clinical Research That Demonstrates Oxyjun® Terminalia Arjuna Extract Helps Promote Cardiac Output And Reduce Physical Fatigue


Innophos is the exclusive licensed distributor of Oxyjun® in North America

Cardiac health is of the utmost importance for today’s consumers, and we are excited about the beneficial findings of Oxyjun® from this study.

Innophos, a leading international producer of nutritional specialty ingredients and custom formulated solutions, today announced the release of new clinical findings from ENovate Biolife highlighting Oxyjun®, a premium branded extract of Terminalia arjuna. Extracted from the bark of the Arjuna tree, Terminalia arjuna has traditionally been used for cardio protection purposes. The findings from this latest human clinical trial demonstrate advanced benefits in the areas of cardiac output and perceived reduction in physical fatigue in study subjects.

“Cardiac health is of the utmost importance for today’s consumers, and we are excited about the beneficial findings of Oxyjun® from this study,” said Dr. Bruce Abedon, R&D Senior Manager at Innophos and co-author of the study. “As the exclusive licensed distributor of Oxyjun® in North America, our team at Innophos is committed to providing the highest quality, science-backed products, and continuing our partnership with ENovate Biolife.”

The new study, published in the peer-reviewed Journal of Multidisciplinary Health, featured 72 male and female subjects ranging in age from 30-70 years old that took 400 mg of Oxyjun® daily for 56 days. Subjects were evaluated on both cardiac output based on left ventricular ejection fraction (the volume of blood flowing from the heart to the body with each beat) as well as their perceived level of physical fatigue based on a validated, multi-question Fatigue Severity Scale instrument.

Consumption of Oxyjun® resulted in numerous improvements in the health of subjects including:

  • 6.28% increase in cardiac output (vs. 0.24% for placebo)
  • 22.5% perceived reduction in physical fatigue (vs. 8.5% for placebo)
  • No adverse events related to consumption of Oxyjun® for any of the study participants

Find out more about the study’s findings at PubMed and visit the Innophos website to learn more about the benefits of Oxyjun.

Oxyjun® is a registered trademark of ENovate Biolife LLC.

*These statements have not been evaluated by the Food and Drug Administration. This ingredient is not intended to diagnose, treat, cure, or prevent any disease.

About Innophos

Innophos is a leading international producer of specialty ingredient solutions that deliver far-reaching, versatile benefits for the food, health, nutrition, and industrial markets. We leverage our expertise in the science and technology of blending and formulating phosphate, mineral, enzyme, and botanical based ingredients to help our customers offer products that are tasty, healthy, nutritious, and economical. Headquartered in Cranbury, New Jersey, Innophos has manufacturing operations across the United States, in Canada, Mexico, a

Share article on social media or email:

Partnerships with Oracle and Google help drive record growth in 2022


News Image

We are thrilled to end the year on such a strong note and are excited to continue this momentum in the coming year

Goliath Technologies, a leader in end-user experience monitoring and troubleshooting software, ended 2022 on a high note with significant growth in both employee headcount and revenue. The company also added 50 new enterprise clients thanks to strong demand for Goliath’s industry-leading solutions.

“We had another record year in 2022, making this the third consecutive year of continued growth. We achieved this by further investing in our products, partnerships, and people so we could continue to expand at an increasing pace,” noted Thomas Charlton, Chairman and CEO of Goliath.

In addition to this impressive growth, Goliath Technologies made waves in the industry with the release of its new monitoring and troubleshooting solution for ChromeOS devices. This solution, which is the only one of its kind on the market, helps IT professionals proactively identify and resolve end-user experience issues on ChromeOS devices, ensuring successful ChromeOS device deployments.

Goliath Technologies also made strides in its commitment to industry collaboration including becoming a member of KLAS, a leading healthcare technology research firm. A recent KLAS case study on the improved reliability and response time of Intermountain Healthcare’s EHR showed that the use of Goliath Technologies’ solution was key to success, resulting in an increase of 26% in reliability, 22% in systems response, and 15% in delivery quality.

“Collaboration is key to ensuring we are developing the best possible solutions for our customers,” says Keary Pence, Director of Product Marketing at Goliath. “We are uniquely positioned with industry-only partnerships and are looking to expand our partnerships even more in 2023.”

As part of Goliath’s impressive growth and team expansion in 2022, Shawn Brady was appointed as Chief Revenue Officer. Brady is a veteran high-tech leader and sales executive, overseeing the global sales organization and client success teams as the company enters its next phase of growth. Another key hire was Keary Pence, Director of Product Marketing. Keary brings a breadth of industry experience across marketing, enablement, sales, and channel teams at leading technology organizations.

“We are thrilled to end the year on such a strong note and are excited to continue this momentum in the coming year,” said Charlton. “Our team has worked hard to deliver innovative solutions that meet the needs of our customers, and we are looking forward to expanding our capabilities even further in 2023.”

About Goliath Technologies

Goliath Technologies offers end-user experience monitoring and troubleshooting software, with embedded intelligence and automation, that enables IT pros to anticipate, troubleshoot, and document performance issues regardless of where workloads, applications, or users are located. By doing so, Goliath helps IT break out of reactive mode, and into proactive mode. Customers include Universal Health Services, NorthBay Healthcare, Enterprise Rent-A-Car, Penn National Insurance, American Airlines, Office Depot, Tech Mahindra, Pacific Life, Xerox, HCL, and others. Learn more about how we empower proactive IT at goliathtechnologies.com.

Share article on social media or email: